Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR115 in ARID1A-Mutated Advanced Solid Tumors
NCT07793318Phase 2Not yet recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of TR115 in solid tumor, ovarian clear cell carcinoma (OCCC), endometrial cancer (EC), gastric cancer (GC), urothelial carcinoma (UC), sponsored by Tarapeutics Science Inc. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
TR115
03
Conditions
solid tumorovarian clear cell carcinoma (OCCC)endometrial cancer (EC)gastric cancer (GC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07793318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793318.